Table 2.
Characteristics of patients included in the retrospective study
| Older patients [n = 27] | Younger patients [n = 19] | |
|---|---|---|
| Age, years | ||
| Median | 79 | 44 |
| Range | 73–93 | 25–59 |
| Localization of the primary tumor | ||
| Ovarian | 23 (85) | 14 (74) |
| Endometrial | 4 (15) | 0 (0) |
| Breast | 0 (0) | 5 (26)a |
| Prior lines of therapy | ||
| 1 | 12 (44) | 14 (74) |
| 2 | 12 (44) | 3 (16) |
| 3 | 1 (4) | 2 (10) |
| 4 | 2 (7) | 0 (0) |
| PARPi | ||
| Olaparib | 17 (63) | 14 (74) |
| Niraparib | 8 (30) | 5 (26) |
| Rucaparib | 2 (7) | 0 (0) |
| Relative dose intensity [median (SD)]b | 67% (± 24%) | 88% (± 23%) |
| Known hematological disease | ||
| None | 27 (100) | 19 (100) |
| Concomitant hematotoxic treatment | 0 (0) | 0 (0) |
Data are expressed as n (%) unless otherwise specified
PARPi poly(ADP-ribose) polymerase inhibitors, SD standard deviation
ap = 0.009
bRelative dose intensity was computed considering the full dose described in the treatment approval